The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
Open accessAbstract
Angiogenesis, a process of new blood vessel formation, is a prerequisite for tumour growth to supply the proliferating tumour with oxygen and nutrients. The angiogenic process may contribute to tumour progression, invasion and metastasis, and is generally accepted as an indicator of tumour prognosis. Therefore, targeting tumour angiogenesis has become of high clinical relevance. The current review aimed to highlight mechanistic details of anti‐angiogenic therapies and how they relate to classification and treatment rationales. Angiogenesis inhibitors are classified into either direct inhibitors that target endothelial cells in the growing vasculature or indirect inhibitors that prevent the expression or block the activity of angiogenesis inducers. The latter class extends to include targeted therapy against oncogenes, conventional chemotherapeutic agents and drugs targeting other cells of the tumour micro‐environment. Angiogenesis inhibitors may be used as either monotherapy or in combination with other anticancer drugs. In this context, many preclinical and clinical studies revealed higher therapeutic effectiveness of the combined treatments compared with individual treatments. The proper understanding of synergistic treatment modalities of angiogenesis inhibitors as well as their wide range of cellular targets could provide effective tools for future therapies of many types of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–226 of 226
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo
Klenke, F. M., Abdollahi, A., Bertl, E., Gebhard, M. M., Ewerbeck, V., Huber, P. E., & Sckell, A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-49 · Cited by 59
Fujita, M., Khazenzon, N. M., Ljubimov, A. V., Lee, B., Virtanen, I., Holler, E., Black, K. L., & Ljubimova, J. Y. (2006) · Angiogenesis · doi:10.1007/s10456-006-9046-9 · Cited by 58
Lammerts, E., Roswall, P., Sundberg, C., Gotwals, P. J., Koteliansky, V., Reed, R. K., Heldin, N., & Rubin, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10722 · Cited by 55
Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients
Nakashima, T., Huang, C. Y., Liu, D., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600955 · Cited by 55
Diabetic Retinopathy: Current Management and Experimental Therapeutic Targets
Ali, T. K., & El‐Remessy, A. B. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.2.182 · Cited by 55
Self-citationSchuster, C., Eikesdal, H. P., Puntervoll, H. E., Geisler, J., Geisler, S. B., Heinrich, D., Molven, A., Lønning, P. E., Akslen, L. A., & Straume, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038364 · Cited by 53
Awada, A. H., Eskens, F. A. L. M., Piccart, M. J., Cutler, D. L., van der Gaast, A., Bleiberg, H., Wanders, J., Faber, M. N., Statkevich, P., Fumoleau, P., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00379-9 · Cited by 52
Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib
Ma, J., & Waxman, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1174 · Cited by 52
Antiangiogenesis Enhances Intratumoral Drug Retention
Ma, J., Chen, C.-S., Blute, T. A., & Waxman, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3242 · Cited by 51
Meyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A.-W., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 51
Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion
Stathopoulos, G. T., Moschos, C., Loutrari, H. V., Kollintza, A., Psallidas, I., Karabela, S. P., Magkouta, S., Zhou, Z., Papiris, S. A., Roussos, C., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1513oc · Cited by 50
Mueller, J., Gaertner, F. C., Blechert, B., Janssen, K., & Essler, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0538 · Cited by 50
Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
Burstein, H. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2684 · Cited by 48
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
Elice, F., & Rodeghiero, F. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70014-1 · Cited by 46
Bello, E., Taraboletti, G., Colella, G., Zucchetti, M., Forestieri, D., Licandro, S. A., Berndt, A., Richter, P., D’Incalci, M., Cavalletti, E., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0275-t · Cited by 45
Nelius, T., Rinard, K., & Filleur, S. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.12.006 · Cited by 41
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-κB Activity
Matsuo, Y., Sawai, H., Ochi, N., Yasuda, A., Sakamoto, M., Takahashi, H., Funahashi, H., Takeyama, H., & Guha, S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0814-4 · Cited by 41
Kim, R., Emi, M., Arihiro, K., Tanabe, K., Uchida, Y., & Toge, T. (2005) · Cancer · doi:10.1002/cncr.20973 · Cited by 35
Moser, C., Lang, S. A., Hackl, C., Wagner, C., Scheiffert, E., Schlitt, H. J., Geissler, E. K., & Stoeltzing, O. (2012) · PubMed · Cited by 35
Papageorgiou, A., Kamat, A. M., Benedict, W. F., Dinney, C. P., & McConkey, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0474 · Cited by 35
Figlin, R. A., Kondagunta, G. V., Yazji, S., Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4535 · Cited by 31
Kim, C., Choi, Y. K., Lee, H., Ha, K., Won, M., Kwon, Y., & Kim, Y.-M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.063586 · Cited by 30
Evans, T., Ramanathan, R. K., Yazji, S., Glynne‐Jones, R., Anthoney, A., Berlin, J. D., & Valle, J. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4549 · Cited by 27
Maintenance therapy in colon cancer
Giuliani, F., Vita, F. D., Colucci, G., & Pisconti, S. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70019-0 · Cited by 25
Lee, J., & Lee, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.401554 · Cited by 25
Fabi, A., Russillo, M., Ferretti, G., Metro, G., Nisticò, C., Papaldo, P., Vita, F. D., D’Auria, G., Vidiri, A., Giannarelli, D., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-482 · Cited by 22
Cited by
The Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Recent discoveries of anticancer flavonoids
Raffa, D., Maggio, B., Raimondi, M. V., Plescia, F., & Daidone, G. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.034 · Cited by 339
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299
Metadata
- Authors
- El‐Kenawi, A. E., & El‐Remessy, A. B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-10
- Volume
- 170
- Issue
- 4
- Pages
- 712-729
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1543678657
- Cited by
- 253
- References
- 226
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
